PeptideStack
5.2kquestions
20kanswers
220users

What does SURPASS-2 actually establish about tirzepatide?

Asked 25 May 2026Modified 2 months agoViewed 385 times
This question was closed as needing more focus.Closed 7 Jun 2026. Answers already posted are preserved; new answers are not accepted. Questions here should ask one identifiable thing.
1

What I am working with: SURPASS-2 · tirzepatide.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

How should I read this, and where are the traps?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionscardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
BA
askedben_akintola10k1625 May 2026
6Is that the primary endpoint or a secondary one? They get quoted interchangeably. – Dr_Nadia_Farsi 2 months ago
7Do you have the population it was measured in? The figure moves a lot between them. – ten_mg_vial 4 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 385 times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.